Core Viewpoint - HUTCHMED has successfully renewed contracts with the China National Healthcare Security Administration (NHSA), ensuring the inclusion of its drugs ELUNATE, ORPATHYS, and SULANDA in the updated National Reimbursement Drug List (NRDL) effective January 1, 2026, and the addition of TAZVERIK to the National Commercial Health Insurance Innovative Drug List [1][4]. Group 1: Drug Inclusion and Details - ELUNATE (fruquintinib) is included for treating advanced endometrial cancer with pMMR tumors and metastatic colorectal cancer patients who have undergone prior chemotherapy [2]. - ORPATHYS (savolitinib) is included for adult patients with locally advanced or metastatic non-small cell lung cancer with MET exon 14 skipping alteration [3]. - SULANDA (surufatinib) is renewed for treating unresectable, locally advanced or metastatic, progressive non-functional well-differentiated neuroendocrine tumors [3]. - TAZVERIK (tazemetostat) is included in the Commercial Insurance Drug List for adult patients with relapsed or refractory follicular lymphoma with EZH2 mutation [4]. Group 2: Reimbursement Framework - The new Commercial Insurance Drug List, established by the NHSA, focuses on innovative medicines with significant clinical value, enabling reimbursement through various commercial health insurance products [4]. - As of the end of 2024, approximately 1.33 billion people in China had basic medical insurance coverage, representing around 95% of the population, highlighting the government's commitment to improving drug affordability [5]. Group 3: Company Overview - HUTCHMED is an innovative biopharmaceutical company focused on the discovery, development, and commercialization of targeted therapies and immunotherapies for cancer and immunological diseases [10]. - The company has successfully brought its first three medicines to market in China, with one also approved globally [10].

Group 1 - The core point of the article is that Heng Rui Medicine has received conditional approval from the National Medical Products Administration for its self-developed innovative drug, SHR2554 tablets, for adult patients with relapsed or refractory peripheral T-cell lymphoma who have previously undergone at least one line of systemic therapy [1] Group 2 - SHR2554 tablets are the first self-developed EZH2 inhibitor in China, representing a new, efficient, and selective oral EZH2 inhibitor [2] - The global sales of Tazverik, an EZH2 inhibitor developed by Epizyme, are projected to reach approximately $51 million in 2024 [2] - The cumulative R&D investment for SHR2554 tablets has reached approximately 213 million yuan [2]